Exact Sciences Corp. (Nasdaq: EXAS) has earned a place in Deloitte’s Technology Fast 500. The annual list ranks the fastest-growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors. Exact Sciences ranked 110th on the list with 852-percent revenue growth from 2012 to 2015, the measurement period for the list. The median revenue growth of companies on the list was 290 percent.

In 2014, Exact Sciences received approval from the U.S. Food and Drug Administration to market Cologuard, the company’s non-invasive, DNA-based colon cancer screening test. Since Cologuard’s launch shortly after FDA approval, more than 50,000 providers have ordered test and more than a quarter-million tests have been completed.

“Our mission at Exact Sciences is to help more people get screened for colon cancer,” said Kevin Conroy, the company’s chairman and CEO. “The company’s inclusion in the 2016 Technology Fast 500 speaks volumes about the power of Cologuard and its ability to help us fulfill our mission.”

Forty-two percent of those screened with Cologuard have never been screened before for colon cancer.

“Our Technology Fast 500 ranking also is a great tribute to the incredibly talented, dedicated team at Exact Sciences, all of whom are committed to our mission and working hard to serve both providers and patients,” Mr. Conroy said.

The Technology Fast 500 is an annual project of Deloitte’s Technology, Media and Telecommunications practice, which serves 1,800 clients in the United States.

About Cologuard 
Cologuard was approved by the FDA in August 2014 and results from Exact Sciences’ prospective 90-site, point-in-time, 10,000-patient pivotal trial were published in the New England Journal of Medicine in March 2014. Cologuard is included in the recommendations of the U.S. Preventive Services Task Force (2016) and the American Cancer Society’s (2014) colorectal cancer screening guidelines. Stool DNA is included in the combined screening guidelines of the American Cancer Society/U.S. Multi-Society Task Force/American College of Radiology (2008), the American College of Gastroenterology guidelines (2009) and the National Comprehensive Cancer Network (2016). Cologuard is indicated to screen adults of either sex, 50 years or older, who are at average risk for colorectal cancer. Cologuard is not for everyone and is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals. False positives and false negatives do occur. Any positive test result should be followed by a diagnostic colonoscopy. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient. Cologuard performance when used for repeat testing has not been evaluated or established. For more information about Cologuard, visit www.CologuardTest.com. Rx Only.

About Exact Sciences Corp. 
Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. For more information, please visit the company’s website at www.exactsciences.com, follow Exact Sciences on Twitter @ExactSciences or find Exact Sciences on Facebook.


Read the full press release at exactsciences.com here.